Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.
Salvatore Siena, MD
Advertisement
Articles by Salvatore Siena, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
4
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
5